Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

被引：1

作者：

Nishimura, Noriko ^{[1
]}

Brown, Samantha ^{[2
]}

Devlin, Sean M. ^{[3
]}

Dahi, Parastoo B. ^{[4
,5
]}

Landau, Heather ^{[4
,6
]}

Lahoud, Oscar B. ^{[6
]}

Scordo, Michael ^{[4
,6
]}

Shah, Gunjan L. ^{[4
,7
]}

Hassoun, Hani ^{[8
]}

Hultcrantz, Malin ^{[8
]}

Korde, Neha ^{[8
]}

Lesokhin, Alexander M. ^{[5
,9
]}

Mailankody, Sham ^{[5
]}

Shah, Urvi A. ^{[8
]}

Tan, Carlyn ^{[8
]}

Usmani, Saad ^{[10
]}

Giralt, Sergio A. ^{[4
,11
]}

Chung, David J. ^{[4
,6
]}

Gupta, Gaurav ^{[12
]}

Maryamchik, Elena ^{[12
]}

Ntrivalas, Evangelos ^{[13
]}

Roshal, Mikhail ^{[14
]}

机构：

[1] Sloan Kettering Inst Canc Res, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[4] Weill Cornell Med Coll, Dept Med, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, Cellular Therapy Serv, 1275 York Ave, New York, NY 10021 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA

[9] Weill Cornell Med Coll, New York, NY USA

[10] Levine Canc Inst, New York, NY USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, 1275 York Ave, New York, NY 10021 USA

[12] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Transfus Med & Cell Therapy, 1275 York Ave, New York, NY 10021 USA

[13] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Cellular Immunol Serv, 1275 York Ave, New York, NY 10021 USA

[14] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Hematopathol Serv, 1275 York Ave, New York, NY 10021 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
Liu, Jiahui
Yan, Wenqiang
Fan, Huishou
Xu, Jingyu
Li, Lingna
Du, Chenxing
Mao, Xuehan
Yan, Yuting
Xu, Yan
Sui, Weiwei
Deng, Shuhui
Yi, Shuhua
Anderson, Kenneth C.
Qiu, Lugui
Zou, Dehui
An, Gang
CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1770 - 1780
[42] Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
Mohan, Meera
Gundarlapalli, Sravani
Szabo, Aniko
Yarlagadda, Naveen
Kakadia, Sunilkumar
Konda, Manojna
Jillella, Anusha
Fnu, Amisha
Ogunsesan, Yetunde
Yarlagadda, Lakshmi
Thalambedu, Nishant
Munawar, Hussain
Graziutti, Monica
Al Hadidi, Samer
Alapat, Daisy
Thanendrarajan, Sharmilan
Zangari, Maurizio
van Rhee, Frits
Schinke, Carolina
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E195 - E198
[43] Serum free light-chain measurements for monitoring minimal residual disease after stem cell transplantation in multiple myeloma patients
De Souza, C. A.
Oliveira-Duarte, G.
Dias, D. F.
Bottini, P. V.
Vigorito, A. C.
Aranha, F. J. P.
Eid, K. A. B.
Lorand-Metze, I.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 433 - 433
[44] POINT Should minimal residual disease negativity be the end point of myeloma therapy?
Anderson, Kenneth C.
BLOOD ADVANCES, 2017, 1 (08) : 517 - 521
[45] Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients with minimal residual disease
Byun, J. M.
Jung, E. H.
Shin, D. -Y.
Do, Y. R.
Kim, H.
Bae, S. H.
Kim, S. -J.
Kwak, J. -Y.
Lee, S. M.
Yoon, S. -S.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 410 - 411
[46] Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
Landgren, Ola
Weisel, Katja
Dachs, Laura Rosinol
Moreau, Philippe
Turgut, Mehmet
Hajek, Roman
Mollee, Peter
Kim, Jin Seok
Zhang, Jianqi
Go, Ning
Morris, Christopher L.
Usmani, Saad Z.
BLOOD, 2020, 136
[47] Real-world sustained minimal residual disease (MRD) negativity using NGS in multiple myeloma.
Demaree, Audrey
Hewitt, Anthony
Lee, Lik Wee
Eckert, Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[48] Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
Wang, Jing
Li, Jing
Zhang, Run
Li, Jianyong
Chen, Lijuan
Jin, Yuanyuan
DISCOVER ONCOLOGY, 2024, 15 (01)
[49] Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma
Jing Wang
Jing Li
Run Zhang
Jianyong Li
Lijuan Chen
Yuanyuan Jin
Discover Oncology, 15
[50] Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
D'Agostino, Mattia
Bertuglia, Giuseppe
Rota-Scalabrini, Delia
Belotti, Angelo
More, Sonia
Corradini, Paolo
Oliva, Stefania
Ledda, Antonio
Grasso, Mariella
Pavone, Vincenzo
Ronconi, Sonia
Vincelli, Iolanda Donatella
Ballanti, Stelvio
Velluti, Cristina
Cellini, Claudia
Gozzetti, Alessandro
Palmas, Angelo D.
Gamberi, Barbara
Mancuso, Katia
Paris, Laura
Zambello, Renato
Petrucci, Maria Teresa
Bruno, Benedetto
Musto, Pellegrino
Gay, Francesca
BLOOD, 2024, 143 (07) : 592 - 596

← 1 2 3 4 5 →